Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C

Okuse, Chiaki; Yotsuyanagi, Hiroshi; Nagase, Yoshihiko; Kobayashi, Yuhtaro; Yasuda, Kiyomi; Koike, Kazuhiko; Iino, Shiro; Suzuki, Michihiro; Itoh, Fumio

doi:10.3748/wjg.v12.i23.3756

Cited by 55 publications

(57 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data further suggested that anemia worsened with increasing therapy duration of more than 6 months, consistent with previous reports anemia being most common side-effect of Interferon and Ribavirin therapy possibly due to direct toxic effects of ribavirin on RBCs promoting hemolysis [18]. Studies have also shown that Interferon therapy in HCV patients with hypertension can induce or aggravate retinopathy possibly due to narrowing of arteries affecting retinal microcirculation [19]. Interferon therapy can also induce skin, CVS and musculoskeletal side effects [20] and can precipitate or perpetrate pathological events favoring autoimmune diseases [21].…”

Section: Discussionsupporting

confidence: 91%

Impact of duration of therapy on side effect profile of anti-HCV protocol: A retrospective cohort study from two tertiary health facilities in Pakistan

Saleem¹,

Saeed²,

Hashmi³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Impact of duration of therapy on side effect profile of anti-HCV protocol: A retrospective cohort study from two tertiary health facilities in Pakistan

Saleem¹,

Saeed²,

Hashmi³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…IFN-related retinopathy in hepatitis C patients (most commonly CWS) has been reported in 18-86% of patients [3,5,6,[8][9][10]. The wide range of retinopathy reflects limitations of small studies, retrospectively collected data, differences in population, exclusion or inclusion of diabetic or hypertension patients, absence of baseline eye exams, variation in interferon type and dose and finally differences in timing and frequency of eye exams [3].…”

Section: Discussionmentioning

confidence: 99%

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

et al. 2009

View full text Add to dashboard Cite

The purpose of this study is to evaluate the incidence and outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. A total of 74 hepatitis C patients with baseline eye exams and eye exams during therapy were included. Retinopathy was defined as development of cotton wool spots and/or intra-retinal hemorrhage. Demographics, hepatitis C viral characteristics, treatment and laboratory data, and eye exam findings were compared in groups with and without retinopathy. Retinopathy developed in 28 (38%), early in therapy. Pre-treatment eye exams did not predict risk of retinopathy. Therapy was continued in all but one; cotton wool spots resolved in 24 of 26. All nine patients with intra-retinal hemorrhage had resolution. No patient had retinopathy-related visual deterioration. Retinopathy is common with peginterferon therapy, but the outcome is favorable. Cessation of therapy for retinopathy is not warranted. Severe visual disturbances and scotomas deserve further evaluation.

show abstract

“…In 10 (71%) patients, retinopathy regressed within 4-8 weeks during treatment. This situation shows that the treatment can be continued in many patients despite retinopathy (6).…”

Section: Resultsmentioning

confidence: 89%

Kronik Hepatit B ve Hepatit C Hastalarında Pegile-İnterferon-Alfa Tedavisi Öncesi ve Sonrası Göz Bulguları

Köse¹,

Türken²,

Kuzucu³

et al. 2014

vhd

View full text Add to dashboard Cite

Viral Hepatitis Journal, pub lis hed by Ga le nos Pub lis hing. ABS TRACTObjective: Interferons are used in the treatments of chronic hepatitis B and C since they inhibit viral replication and have immunomodulatory effects. Common side effects include: flu-like syndrome, hematologic abnormalities, cardiovascular system and gastrointestinal system symptoms, diabetes, autoimmune disorders, pulmonary dysfunction, and suffering from depression. In this study, the development of retinopathy, a rare side effect of interferon, was aimed to be investigated. Materials and Methods: Forty-three patients with hepatitis B and C followed-up in İzmir Tepecik Training and Research Hospital, Infectious Diseases outpatient clinic were included in the study. Pegylated-interferon-alpha therapy was initiated in all patients. Fundus examination results of patients who completed 48 weeks of treatment were evaluated before and after the treatment. Results: Diabetic retinopathy (DRP) was determined in a patient before treatment (proliferative DRP on left and right). Arteriosclerotic fundus vessels in another patient were determined. After the treatment, the findings in these patients were still the same. However, retinopathy was detected in fundus examination in one (2.32%) patient, although it was found to be normal before the treatment. Conclusion:The patients who developed retinopathy due to interferon should be closely monitored, risk factors should be investigated, and if necessary, the treatment should be performed. Discontinuation of interferon therapy is usually required in case of development of retinopathy. (Viral Hepatitis Journal 2014; 20(1): 1-3)

show abstract

Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C

Abstract: Retinopathy associated with combination therapy of interferon alpha-2b and ribavirin tends to develop in patients with hypertension.

Cited by 55 publications

References 14 publications

Impact of duration of therapy on side effect profile of anti-HCV protocol: A retrospective cohort study from two tertiary health facilities in Pakistan

Impact of duration of therapy on side effect profile of anti-HCV protocol: A retrospective cohort study from two tertiary health facilities in Pakistan

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

Kronik Hepatit B ve Hepatit C Hastalarında Pegile-İnterferon-Alfa Tedavisi Öncesi ve Sonrası Göz Bulguları

Contact Info

Product

Resources

About